AdAlta CEO Sam Cobb Discusses IPF Therapy Development
Rare Disease Report sat down with AdAlta CEO Sam Cobb to discuss the impetus for the redesign of AD-214, and what it means for those in the idopathic pulmonary fibrosis.
Read More